Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate
All-Stock Deal Merges Two San Diego Firms
Deal Snapshot: Equillium will gain $33m, extending its cash runway into 2024 and past several upcoming milestones, but it will seek a strategic partner for Metacrine’s stalled FXR agonist MET642.
You may also be interested in...
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.